Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.

摘要: To investigate further the antiangiogenic potential of sunitinib for renal cell carcinoma (RCC) treatment, its effects on tumor vasculature were monitored by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) using an orthotopic KCI-18 model human RCC xenografts in nude mice. Tumor-bearing mice treated with various doses sunitinib, and vascular changes assessed DCE-MRI histologic studies. Sunitinib induced dose-dependent changes, which observed both kidney tumors normal kidneys DCE-MRI. A dosage 10 mg/kg per day caused mild Gd uptake clearance kinetics tumors. 40 increased permeability retention, probably resulting from destruction vasculature, also alterations vessels. However, at 20 perfusion decreased associated thinning regularization vessels while mildly affecting as confirmed diagnosis. Alterations resulted a significant inhibition growth dosages day. exerted direct cytotoxic effect cells vitro. expressed endothelial factor receptor 2 platelet-derived β molecular targets that modulated drug treatment. These data suggest day, inhibits regularizes milder vessels, could be used to improve blood flow combination chemotherapy. studies emphasize clinical selecting dose schedule compounds.